Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Marzeptacog Alfa (Activated) for Bleeding Prophylaxis in Hemophilia A and B with Inhibitors
NCT03407651Phase 2Completed
- Sponsor
- Gyre Therapeutics, Inc.
- Start
- Dec 2017
- Primary completion
- Mar 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
A Phase 2 trial of marzeptacog alfa (activated) in hemophilia A, hemophilia B (HB), sponsored by Gyre Therapeutics, Inc.. Started Dec 2017; status: completed.
02
Drugs
marzeptacog alfa (activated)
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT03407651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03407651.